Science says it's safe, but some in France don't trust AstraZeneca vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Thursday
December 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
THURSDAY, DECEMBER 07, 2023
Science says it's safe, but some in France don't trust AstraZeneca vaccine

Coronavirus chronicle

Reuters
08 March, 2021, 09:00 pm
Last modified: 08 March, 2021, 09:04 pm

Related News

  • Crowds join lawmakers in Paris march against antisemitism
  • Two killed in shooting in France's Marseille
  • Gaza activist on speaking tour in France detained, awaiting deportation
  • Few expectations as France seeks tangible results at Gaza conference
  • Paris to send tents, medicine in humanitarian shipment to Gaza

Science says it's safe, but some in France don't trust AstraZeneca vaccine

According to the most recent data made available by the French health ministry, for the end of February, France was using 24% of its AstraZeneca doses, compared with 82% for vaccines made by Pfizer/BioNTech and 37% for the Moderna shot

Reuters
08 March, 2021, 09:00 pm
Last modified: 08 March, 2021, 09:04 pm
The vaccine allegedly "stimulates broad antibody and T cell functions Photo: Medical Xpress
The vaccine allegedly "stimulates broad antibody and T cell functions Photo: Medical Xpress

A 60-year-old recovering from breast cancer, Paris resident Nadine Roger is at high-risk from Covid-19 and wants to get vaccinated as soon as possible. Yet when she was offered the vaccine manufactured by AstraZeneca she turned it down.

"The AstraZeneca (shot) frightens me," she said. Roger, a medical technician, said she would wait instead for the shot made by US firm Johnson & Johnson, which has not yet been approved by European regulators.

According to the most recent data made available by the French health ministry, for the end of February, France was using 24% of its AstraZeneca doses, compared with 82% for vaccines made by Pfizer/BioNTech and 37% for the Moderna shot.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

That is partly due to logistical bottlenecks, but also because some French people don't trust the AstraZeneca shot - despite multiple scientific studies that indicate it is safe and effective - according to interviews Reuters conducted with eight people involved in France's vaccine rollout.

They said some of those offered the vaccine were worried about side-effects, sceptical it was effective against new variants of Covid-19, and confused by shifting evidence on how well it works for older people.

The AstraZeneca vaccine had a bumpy genesis.

European regulators recommended it not be used for people over 65, citing a lack of data. French President Emmanuel Macron was quoted as saying the shot was "quasi-effective" and the French regulator called on hospitals to stagger inoculations of their staff after side effects led frontline workers to call in sick.

"All that sent out the wrong signal to health workers, but also the rest of the population," said Jacques Battistoni, head of the largest general practitioners' union in France.

CHANGING TACK

To be sure, France is one of the most vaccine-sceptic countries globally, though surveys have showed the proportion of the public intending to get inoculated increasing.

Like other wealthy countries, France has made the AstraZeneca shot a pillar of its vaccine rollout. With all the big vaccine makers experiencing production problems, countries cannot afford for people to snub one of the shots.

A health ministry official and two doctors involved in the rollout said the uptake was accelerating as logistics improve and people get used to the AstraZeneca shot.

AstraZenaca doses were initially to be delivered to hospitals and vaccination centres for the inoculation of healthcare workers, and to general practitioners for the vaccination of 50 to 64-year-olds with pre-existing conditions.

In the first week of the AstraZenaca rollout, which coincided with the start of school holidays, GPs ordered fewer than half of their allocated doses.

The president of AstraZeneca France, Olivier Nataf, told the weekly Journal du Dimanche at the weekend that his company's vaccine was entirely effective against severe Covid-19 infections and 80% effective in preventing hospitalizations.

"Confusions and disappointments can arise. Many are already resolved," he told the newspaper. "There may be others. But the enemy remains the pandemic. Any controversy diminishes our ability to overcome it."

European regulators have concluded the side-effects cause by the AstraZenaca vaccine are not a cause to doubt its safety. A study in Scotland covering 5.4 million people showed it, and the Pfizer vaccine, were highly effective in preventing severe infections.

France, Germany and Italy have changed tack and are now giving the vaccine to people over 65.

Macron said last month the AstraZeneca jab was effective, and he would take it if offered.

'SECOND-RATE VACCINE'

But some doubts linger. Malika, a 54-year-old who works in a clinic for homeless people near Paris, said she turned down the AstraZeneca vaccine when offered it.

"I thought to myself: 'I don't really see the point of getting vaccinated with a second-rate vaccine'," said Malika, who did not want her family name published.

She said her mind was made up when a colleague had the shot and experienced side-effects. Malika said wanted to have the Pfizer jab, currently reserved for over-75s, instead.

Roger, the cancer survivor, said she lived alone, so was worried about coming down with a fever, one of the possible side-effects from Covid-19 vaccines, and had doubts about the AstraZeneca vaccine's efficacy against new variants.

But the big drawback, she said, was that she would have to wait until getting a second AstraZeneca shot in May to feel fully protected, an issue that would not arise with the one-shot Johnson & Johnson vaccine.

She has been to Yemen, Mali, and Madagascar, and the shelves of her home are decorated with artefacts she brought home. Since her cancer diagnosis, she said she realised she needed to make the most of the time she has, and get back on the road.

"Right now, AstraZeneca doesn't allow me to do that."

Covid-19 Vaccination / AstraZeneca Covid-19 Vaccine / Coornavirus / France

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Deepening dollar crisis: Unveiling causes and solutions
    Deepening dollar crisis: Unveiling causes and solutions
  • Current account surplus drops by 80% in one month
    Current account surplus drops by 80% in one month
  • EC publishes full list of 96 local election observers with 29 new names
    EC publishes full list of 96 local election observers with 29 new names

MOST VIEWED

  • This file photo from December 2019 shows a rider driving his motorcycle through cold wind and fog. A scene not yet visible this year. Photo: Mumit M
    Woe for seasonal crops, vegetables as winter comes late 
  • Caption: Illustration: TBS
    Source tax on land registration cut again
  • File Photo: Reuters
    $1.08 billion could be added to Bangladesh's dwindling forex reserves
  • Photo: Courtesy
    Woman entrepreneur Sangeeta Khan dies at age 62
  • 59 DSE stocks face downgrade to junk category
    59 DSE stocks face downgrade to junk category
  • Dollar pressure rises as short-term foreign debt drops $300m in October
    Dollar pressure rises as short-term foreign debt drops $300m in October

Related News

  • Crowds join lawmakers in Paris march against antisemitism
  • Two killed in shooting in France's Marseille
  • Gaza activist on speaking tour in France detained, awaiting deportation
  • Few expectations as France seeks tangible results at Gaza conference
  • Paris to send tents, medicine in humanitarian shipment to Gaza

Features

Sketch: TBS

How Khan Farhana built a 300,000-strong LinkedIn community

2h | Pursuit
Photo: Courtesy

Fostering emotional intelligence and classroom harmony: The power of a complaint box

2h | Pursuit
Photo: Rexy Jason Gomez

A big love for the small wheels

8h | Features
Dhaka’s FDC,  Japan Garden City and Shia Masjid were all part of Gudaraghat once. PHOTOS:  Syed Zakir Hossain

What the remaining Gudaraghats remind us of Dhaka's long-lost water bodies

15h | Panorama

More Videos from TBS

What is 'obstructing the field' out?

What is 'obstructing the field' out?

7h | TBS SPORTS
When Farooki is hero

When Farooki is hero

5h | TBS Entertainment
Most Ukrainians are losing interest in going to war

Most Ukrainians are losing interest in going to war

9h | TBS World
Putin to visit UAE and Saudi Arabia

Putin to visit UAE and Saudi Arabia

11h | TBS World
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]